<?xml version="1.0" encoding="UTF-8"?>
<p>.Indeed, using the ethoxzolamide 
 <bold>72</bold>, a CAI in clinical use for decades as lead molecule, a multitude of primary sulphonamides (e.g. compounds 
 <bold>73–75</bold>) as well as the secondary siulfonamide 76 were reported to act as highly efficient, frequently low nanomolar inhibitors against the tumour-associated isoforms CA IX and XII
 <xref rid="CIT0084" ref-type="bibr">
  <sup>84–91</sup>
 </xref>. No 
 <italic>ex vivo</italic> or 
 <italic>in vivo</italic> studies are available so far with these potent CA IX/XII inhibitors, but compounds belonging to other classes of sulphonamides were proved to possess significant antitumor effects in vivo when they act as potent inhibitors of these two CA isoforms
 <xref rid="CIT0078" ref-type="bibr">
  <sup>78</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0092" ref-type="bibr">
  <sup>92–98</sup>
 </xref>. Thus future studes may address this issue, considering the fact that the BTA scaffold present in these compounds may induce interesting phisico-chemical and pharmacologic properties to the CA IX/XII inhibitors, of which many chemical families are alredy reported
 <xref rid="CIT0099" ref-type="bibr">
  <sup>99–103</sup>
 </xref>.
</p>
